Which has better earnings & valuation, ACTU or GLMD?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A

Is ACTU or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Galmed Pharmaceuticals N/A -73.68% -60.88%

Do analysts rate LPCN or GLMD?

Lipocine presently has a consensus price target of $4.00, indicating a potential upside of 93.24%. Given Lipocine's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lipocine is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LPCN or GLMD?

In the previous week, Lipocine had 8 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 9 mentions for Lipocine and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Lipocine's score of 0.75 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CLRB or GLMD?

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 558.68%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, CLRB or GLMD?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A

Is CLRB or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -185.35% -115.42% Galmed Pharmaceuticals N/A -73.68% -60.88%

Does the media prefer CLRB or GLMD?

In the previous week, Cellectar Biosciences had 3 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Galmed Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 0.85 beat Galmed Pharmaceuticals' score of 0.75 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GLMD or DARE?

Dare Bioscience has a consensus target price of $6.50, indicating a potential upside of 670.96%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts prefer TVRD or GLMD?

Tvardi Therapeutics presently has a consensus price target of $18.00, indicating a potential upside of 1,478.95%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tvardi Therapeutics is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVRD or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Galmed Pharmaceuticals N/A -73.68% -60.88%

Does the media refer more to TVRD or GLMD?

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Tvardi Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Galmed Pharmaceuticals (GLMD) Competitors

$4.59 -0.04 (-0.86%)

Closing price 09/9/2026

Extended Trading

$4.59 0.00 (0.00%)

As of 09/9/2026 07:56 PM Eastern

Compare

GLMD vs. ACTU, LPCN, CLRB, DARE, and TVRD

Should you buy Galmed Pharmaceuticals stock or one of its competitors? Galmed Pharmaceuticals's main competitors and comparable companies include Actuate Therapeutics (ACTU), Lipocine (LPCN), Cellectar Biosciences (CLRB), Dare Bioscience (DARE), and Tvardi Therapeutics (TVRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Galmed Pharmaceuticals compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Actuate Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Actuate Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
Galmed Pharmaceuticals	Positive

Actuate Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

Actuate Therapeutics presently has a consensus price target of $10.50, suggesting a potential upside of 1,100.14%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galmed Pharmaceuticals' return on equity of -73.68% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Galmed Pharmaceuticals beats Actuate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Lipocine presently has a consensus price target of $4.00, indicating a potential upside of 93.24%. Given Lipocine's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lipocine is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.1% of Lipocine shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 4.7% of Lipocine shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Lipocine has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Lipocine has higher revenue and earnings than Galmed Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.61	-$9.63M	-$1.79	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

In the previous week, Lipocine had 8 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 9 mentions for Lipocine and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Lipocine's score of 0.75 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lipocine beats Galmed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Cellectar Biosciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

In the previous week, Cellectar Biosciences had 3 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Galmed Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 0.85 beat Galmed Pharmaceuticals' score of 0.75 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 558.68%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -73.68% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Summary

Cellectar Biosciences and Galmed Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Dare Bioscience?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Galmed Pharmaceuticals' return on equity of -73.68% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%
Dare Bioscience	-803.80%	-748.30%	-38.75%

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Galmed Pharmaceuticals has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A
Dare Bioscience	$1.03M	16.10	-$13.40M	-$0.70	N/A

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Dare Bioscience. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Dare Bioscience's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Dare Bioscience	Neutral

Dare Bioscience has a consensus target price of $6.50, indicating a potential upside of 670.96%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Galmed Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Summary

Galmed Pharmaceuticals beats Dare Bioscience on 8 of the 15 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Tvardi Therapeutics presently has a consensus price target of $18.00, indicating a potential upside of 1,478.95%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tvardi Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galmed Pharmaceuticals' return on equity of -73.68% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Galmed Pharmaceuticals has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.13	-$18.21M	-$2.79	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Tvardi Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tvardi Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Galmed Pharmaceuticals beats Tvardi Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.78M	$12.25B	$7.17B	$13.47B
Dividend Yield	N/A	2.65%	2.54%	17.38%
P/E Ratio	-0.30	799.76	274.36	26.32
Price / Sales	N/A	840.59	599.51	86.61
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	0.20	10.64	11.02	6.40
Net Income	-$10.31M	$2.84B	$3.50B	$381.19M
7 Day Performance	N/A	-2.00%	-1.69%	-0.10%
1 Month Performance	18.30%	-6.55%	-6.40%	-4.32%
1 Year Performance	-64.36%	-4.71%	6.47%	1.86%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	1.1855 of 5 stars	$4.59 -0.9%	N/A	-63.5%	$4.78M	N/A	N/A	20	Gap Down High Trading Volume
ACTU Actuate Therapeutics	2.7578 of 5 stars	$0.78 +13.6%	$10.50 +1,247.9%	-87.5%	$18.71M	N/A	N/A	12
LPCN Lipocine	4.1624 of 5 stars	$2.25 +3.9%	$4.00 +78.2%	-38.2%	$18.50M	$1.98M	N/A	14
CLRB Cellectar Biosciences	2.7676 of 5 stars	$1.85 +1.6%	$11.00 +494.6%	-71.1%	$17.49M	N/A	N/A	11	News Coverage
DARE Dare Bioscience	2.7103 of 5 stars	$0.86 +5.8%	$6.50 +654.1%	-61.3%	$16.96M	$1.03M	N/A	24

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. ACTU, LPCN, CLRB, DARE, and TVRD

How does Galmed Pharmaceuticals compare to Actuate Therapeutics?

Summary

How does Galmed Pharmaceuticals compare to Lipocine?

Summary

How does Galmed Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does Galmed Pharmaceuticals compare to Dare Bioscience?

Summary

How does Galmed Pharmaceuticals compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. ACTU, LPCN, CLRB, DARE, and TVRD

How does Galmed Pharmaceuticals compare to Actuate Therapeutics?

Does the media prefer ACTU or GLMD?

Which has more volatility and risk, ACTU or GLMD?

Which has better earnings & valuation, ACTU or GLMD?

Do analysts recommend ACTU or GLMD?

Is ACTU or GLMD more profitable?

Do institutionals and insiders hold more shares of ACTU or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Lipocine?

Do analysts rate LPCN or GLMD?

Do institutionals & insiders believe in LPCN or GLMD?

Is LPCN or GLMD more profitable?

Which has more risk & volatility, LPCN or GLMD?

Which has higher valuation & earnings, LPCN or GLMD?

Does the media refer more to LPCN or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Cellectar Biosciences?

Which has more risk and volatility, CLRB or GLMD?

Which has preferable valuation & earnings, CLRB or GLMD?

Does the media prefer CLRB or GLMD?

Do analysts rate CLRB or GLMD?

Do insiders and institutionals hold more shares of CLRB or GLMD?

Is CLRB or GLMD more profitable?

Summary

How does Galmed Pharmaceuticals compare to Dare Bioscience?

Is GLMD or DARE more profitable?

Do insiders & institutionals believe in GLMD or DARE?

Which has preferable earnings & valuation, GLMD or DARE?

Does the media favor GLMD or DARE?

Do analysts rate GLMD or DARE?

Which has more risk & volatility, GLMD or DARE?

Summary

How does Galmed Pharmaceuticals compare to Tvardi Therapeutics?

Do analysts prefer TVRD or GLMD?

Is TVRD or GLMD more profitable?

Which has better earnings & valuation, TVRD or GLMD?

Does the media refer more to TVRD or GLMD?

Which has more volatility and risk, TVRD or GLMD?

Do insiders and institutionals believe in TVRD or GLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools